Last reviewed · How we verify
Restless legs
Approved treatments
- Neupro · UCB
Rotigotine stimulates dopamine receptors in the brain, which may help treat Parkinson's disease and Restless Legs Syndrome. - Requip · GSK
- Requip · Boehringer Ingelheim
- Neurontin · Generic (originally Parke-Davis/Pfizer)
Binds the alpha-2-delta subunit of voltage-gated calcium channels, modulating neurotransmitter release to treat neuropathic pain and seizures. - Horizant · Azurity
Horizant works by binding to the alpha-2/delta-1 subunit of voltage-dependent calcium channels, reducing the release of excitatory neurotransmitters and alleviating pain. - gabapentine · Dominik Irnich
- Horizant · University of Missouri-Columbia
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Restless legs patent landscape — cliff calendar, originator estates, attackable patents
- Restless legs treatment landscape brief
- Restless legs treatment updates RSS
Frequently asked questions about Restless legs
What drugs treat Restless legs?
Tracked treatments include Neupro, Requip, Neurontin, Horizant, gabapentine.
What is the treatment for Restless legs?
Standard treatment for Restless legs includes Neupro, Requip, Neurontin, Horizant, gabapentine. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: Restless legs patent cliff · Restless legs CI report
- Treatment: Neupro · UCB
- Treatment: Requip · GSK
- Treatment: Requip · Boehringer Ingelheim
- Treatment: Neurontin · Generic (originally Parke-Davis/Pfizer)
- Treatment: Horizant · Azurity
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing